Cambridge Antibody Technology Grants License to Wyeth
Cambridge Antibody Technology announces that Wyeth has exercised an option to license CAT's proprietary antibody phage display libraries for in-house use. The libraries will support Wyeth's activities in therapeutic antibody drug discovery and development across a broad range of therapeutic areas. This option to license CAT's libraries was granted to Wyeth as part of the collaboration agreement entered into in March 1999.
In return for Wyeth's exercise of the option, CAT will receive an upfront License fee. Wyeth has a number of exclusive therapeutic and diagnostic antibody product options related to its use of the library which, if exercised, will result in CAT receiving a product License fee and potential milestone and royalty payments.
Peter Chambre, Chief Executive Officer of CAT, commented "We have developed an excellent relationship with Wyeth over the past four years that has already resulted in Wyeth taking two exclusive product licences to human antibodies identified through work carried out at CAT in collaboration with Wyeth. This collaboration has clearly demonstrated the value of our platform technology and we are pleased that Wyeth has chosen to take this technology in-house."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
